MX360409B - Terapia de combinacion de dosis fija para la enfermedad de parkinson. - Google Patents
Terapia de combinacion de dosis fija para la enfermedad de parkinson.Info
- Publication number
- MX360409B MX360409B MX2014008537A MX2014008537A MX360409B MX 360409 B MX360409 B MX 360409B MX 2014008537 A MX2014008537 A MX 2014008537A MX 2014008537 A MX2014008537 A MX 2014008537A MX 360409 B MX360409 B MX 360409B
- Authority
- MX
- Mexico
- Prior art keywords
- parkinson
- disease
- fixed dose
- dose combination
- combination therapy
- Prior art date
Links
- 229940000425 combination drug Drugs 0.000 title abstract 3
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 abstract 3
- 229960003089 pramipexole Drugs 0.000 abstract 3
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 abstract 3
- 229960000245 rasagiline Drugs 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261585824P | 2012-01-12 | 2012-01-12 | |
| PCT/IL2013/050025 WO2013105092A1 (en) | 2012-01-12 | 2013-01-10 | Fixed dose combination therapy of parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014008537A MX2014008537A (es) | 2014-11-25 |
| MX360409B true MX360409B (es) | 2018-10-30 |
Family
ID=48781101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014008537A MX360409B (es) | 2012-01-12 | 2013-01-10 | Terapia de combinacion de dosis fija para la enfermedad de parkinson. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20150079187A1 (enExample) |
| EP (1) | EP2802319B1 (enExample) |
| JP (1) | JP6243351B2 (enExample) |
| KR (2) | KR102276896B1 (enExample) |
| CN (1) | CN104168896B (enExample) |
| AU (1) | AU2013208653B2 (enExample) |
| CA (1) | CA2860952C (enExample) |
| CY (1) | CY1119793T1 (enExample) |
| DK (1) | DK2802319T3 (enExample) |
| ES (1) | ES2655676T3 (enExample) |
| HU (1) | HUE038029T2 (enExample) |
| IL (1) | IL233572B (enExample) |
| IN (1) | IN2014MN01568A (enExample) |
| LT (1) | LT2802319T (enExample) |
| MX (1) | MX360409B (enExample) |
| NO (2) | NO2802319T3 (enExample) |
| PL (1) | PL2802319T3 (enExample) |
| PT (1) | PT2802319T (enExample) |
| RS (1) | RS56742B1 (enExample) |
| RU (1) | RU2642962C9 (enExample) |
| WO (1) | WO2013105092A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| CN104367565A (zh) * | 2014-11-21 | 2015-02-25 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸普拉克索缓释微丸 |
| CN105147627B (zh) * | 2015-08-19 | 2019-04-12 | 天津红日药业股份有限公司 | 一种含有盐酸普拉克索的药物组合物及其制备方法 |
| CA3072994A1 (en) * | 2017-08-17 | 2019-02-21 | Zi-Qiang Gu | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
| CA3122935A1 (en) * | 2018-12-19 | 2020-06-25 | Galecto Biotech Ab | Amorphous form and process |
| WO2021109880A1 (zh) * | 2019-12-06 | 2021-06-10 | 上海医药集团股份有限公司 | 药物组合物、成套药盒及其应用 |
| WO2023112024A1 (en) * | 2021-12-14 | 2023-06-22 | Pharma Two B Ltd. | Method of treating parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL215263B1 (pl) * | 2002-02-25 | 2013-11-29 | Elan Pharm Inc | Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku |
| WO2005070428A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| KR20060124712A (ko) * | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| US20100092554A1 (en) * | 2007-04-24 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| MX2010013393A (es) * | 2008-06-06 | 2011-06-21 | Pharma Two B Ltd | Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson. |
| CN102186350A (zh) * | 2008-08-19 | 2011-09-14 | 诺普神经科学股份有限公司 | 使用(r)-普拉克索的组合物与方法 |
| RU2734632C2 (ru) * | 2010-02-03 | 2020-10-21 | Фарма Ту Б Лтд. | Составы разагилина с пролонгированным высвобождением и их применение |
-
2013
- 2013-01-10 ES ES13736198.6T patent/ES2655676T3/es active Active
- 2013-01-10 US US14/372,067 patent/US20150079187A1/en not_active Abandoned
- 2013-01-10 IN IN1568MUN2014 patent/IN2014MN01568A/en unknown
- 2013-01-10 HU HUE13736198A patent/HUE038029T2/hu unknown
- 2013-01-10 KR KR1020147022416A patent/KR102276896B1/ko active Active
- 2013-01-10 PT PT137361986T patent/PT2802319T/pt unknown
- 2013-01-10 CA CA2860952A patent/CA2860952C/en active Active
- 2013-01-10 WO PCT/IL2013/050025 patent/WO2013105092A1/en not_active Ceased
- 2013-01-10 NO NO13736198A patent/NO2802319T3/no unknown
- 2013-01-10 MX MX2014008537A patent/MX360409B/es active IP Right Grant
- 2013-01-10 AU AU2013208653A patent/AU2013208653B2/en active Active
- 2013-01-10 KR KR1020207002459A patent/KR20200013791A/ko not_active Ceased
- 2013-01-10 DK DK13736198.6T patent/DK2802319T3/da active
- 2013-01-10 JP JP2014551726A patent/JP6243351B2/ja active Active
- 2013-01-10 RU RU2014132940A patent/RU2642962C9/ru active
- 2013-01-10 EP EP13736198.6A patent/EP2802319B1/en active Active
- 2013-01-10 LT LTEP13736198.6T patent/LT2802319T/lt unknown
- 2013-01-10 RS RS20180050A patent/RS56742B1/sr unknown
- 2013-01-10 PL PL13736198T patent/PL2802319T3/pl unknown
- 2013-01-10 CN CN201380014052.8A patent/CN104168896B/zh active Active
- 2013-09-30 NO NO13840443A patent/NO2901008T3/no unknown
-
2014
- 2014-07-09 IL IL233572A patent/IL233572B/en active IP Right Grant
-
2018
- 2018-01-17 CY CY20181100061T patent/CY1119793T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360409B (es) | Terapia de combinacion de dosis fija para la enfermedad de parkinson. | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| NZ626954A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
| IN2014DN11269A (enExample) | ||
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| IN2015DN03219A (enExample) | ||
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| IL232764A (en) | Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| IL260078B (en) | Therapy used to treat Gaucher disease | |
| PH12013502598A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| PH12015501538A1 (en) | Topical ocular analgesic agents | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| TN2013000336A1 (en) | 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. | |
| NZ631362A (en) | Arry-520 for use in treating cancer in a patient with low aag | |
| UA77604U (ru) | Производное 1,2,4-триазола, проявляющее актопротекторную активность | |
| UA71133U (ru) | Способ восстановления адаптационного потенциала женщин с привычным невынашиванием беременности в разные сроки | |
| UA48739U (ru) | СПОСОБ ЛЕЧЕНИЯ ОСТРЫХ РЕСПИРАТОРНЫХ ЗАБОЛЕВАНИЙ У ТЕЛЯТ|телят| |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |